Page last updated: 2024-11-01

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Depressive Disorder, Major

n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Depressive Disorder, Major in 1 studies

N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Stachowicz, K1
Panczyszyn-Trzewik, P1
Rzezniczek X, S1
Sowa-Kucma, M1

Other Studies

1 other study available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Depressive Disorder, Major

ArticleYear
Cyclooxygenase-2 inhibition affects the expression of down syndrom cell adhesion molecule via interaction with metabotropic glutamate receptor 5.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2022, Volume: 73, Issue:2

    Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arachidonic Acid; Cell Adhesion; C

2022